Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The risk for severe RSV-related outcomes was effectively reduced among children and infants who received nirsevimab in real-world clinical settings.

NHS England » NHS to roll out long-lasting ‘suit of armour’ jab to protect thousands of premature babies from RSV ...

Despite adequate availability of nirsevimab, only about one third of eligible children receive it for respiratory syncytial virus prophylaxis, with uptake varying by race and other social factors.

Nirsevimab Reduced Hospitalizations for Infants With RSV — Monoclonal antibody is highly effective, but in short supply by Katherine Kahn, Staff Writer, MedPage Today December 27, 2023 ...

Vulnerable premature babies who need extra protection against RSV may receive six months’ protection in a long-lasting single ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

According to the CDC’s announcement, there is a limited supply of nirsevimab from the manufacturer for the 2023-2024 RSV season, with prefilled syringes of 100-mg doses in especially short supply.

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

In a logistic regression model, nirsevimab was estimated to be 83% effective in preventing hospitalization from RSV bronchiolitis (95% CI 73.4-89.2) in infants younger than 12 months of age, Naim ...

Nirsevimab demonstrated protectionagainst respiratory syncytial virus diseasein healthy infants in Phase 3 trial PARIS– April 26, 2021 – Positive topline results from the Phase 3 MELODY trial ...

Nirsevimab, a monoclonal antibody recently approved to prevent respiratory syncytial virus-associated lower respiratory disease in newborns and infants, may protect longer than an RSV season ...